These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 31014360)

  • 1. Targeting CLL-1 for acute myeloid leukemia therapy.
    Ma H; Padmanabhan IS; Parmar S; Gong Y
    J Hematol Oncol; 2019 Apr; 12(1):41. PubMed ID: 31014360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
    Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia.
    Morsink LM; Walter RB; Ossenkoppele GJ
    Blood Rev; 2019 Mar; 34():26-33. PubMed ID: 30401586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
    Willier S; Rothämel P; Hastreiter M; Wilhelm J; Stenger D; Blaeschke F; Rohlfs M; Kaeuferle T; Schmid I; Albert MH; Binder V; Subklewe M; Klein C; Feuchtinger T
    Blood; 2021 Feb; 137(8):1037-1049. PubMed ID: 33094319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
    Atilla PA; McKenna MK; Watanabe N; Mamonkin M; Brenner MK; Atilla E
    Cytotherapy; 2022 Mar; 24(3):282-290. PubMed ID: 34955406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
    Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
    J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia.
    Zheng B; Yu SF; Del Rosario G; Leong SR; Lee GY; Vij R; Chiu C; Liang WC; Wu Y; Chalouni C; Sadowsky J; Clark V; Hendricks A; Poon KA; Chu W; Pillow T; Schutten MM; Flygare J; Polson AG
    Clin Cancer Res; 2019 Feb; 25(4):1358-1368. PubMed ID: 29959143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.
    Ngai LL; Ma CY; Maguire O; Do AD; Robert A; Logan AC; Griffiths EA; Nemeth MJ; Green C; Pourmohamad T; van Kuijk BJ; Snel AN; Kwidama ZW; Venniker-Punt B; Cooper J; Manz MG; Gjertsen BT; Smit L; Ossenkoppele GJ; Janssen JJWM; Cloos J; Sumiyoshi T
    Eur J Haematol; 2021 Sep; 107(3):343-353. PubMed ID: 34053123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia.
    Bakker AB; van den Oudenrijn S; Bakker AQ; Feller N; van Meijer M; Bia JA; Jongeneelen MA; Visser TJ; Bijl N; Geuijen CA; Marissen WE; Radosevic K; Throsby M; Schuurhuis GJ; Ossenkoppele GJ; de Kruif J; Goudsmit J; Kruisbeek AM
    Cancer Res; 2004 Nov; 64(22):8443-50. PubMed ID: 15548716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia.
    Li Q; Liang C; Xu X; Zhang C; Cao W; Wang M; Jiang Z; Xing H; Yu J
    Leuk Lymphoma; 2022 Sep; 63(9):2136-2148. PubMed ID: 35481814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.
    Ataca Atilla P; McKenna MK; Tashiro H; Srinivasan M; Mo F; Watanabe N; Simons BW; McLean Stevens A; Redell MS; Heslop HE; Mamonkin M; Brenner MK; Atilla E
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development and functional verification of CAR-T cells targeting CLL-1].
    Chai X; Jin X; Zhao MF
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):102-106. PubMed ID: 35381669
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.
    Darwish NH; Sudha T; Godugu K; Elbaz O; Abdelghaffar HA; Hassan EE; Mousa SA
    Oncotarget; 2016 Sep; 7(36):57811-57820. PubMed ID: 27506934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy.
    Bill M; Aggerholm A; Kjeldsen E; Roug AS; Hokland P; Nederby L
    Br J Haematol; 2019 Mar; 184(5):769-781. PubMed ID: 30520015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
    Leong SR; Sukumaran S; Hristopoulos M; Totpal K; Stainton S; Lu E; Wong A; Tam L; Newman R; Vuillemenot BR; Ellerman D; Gu C; Mathieu M; Dennis MS; Nguyen A; Zheng B; Zhang C; Lee G; Chu YW; Prell RA; Lin K; Laing ST; Polson AG
    Blood; 2017 Feb; 129(5):609-618. PubMed ID: 27908880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up.
    Larsen HØ; Roug AS; Just T; Brown GD; Hokland P
    Cytometry B Clin Cytom; 2012 Jan; 82(1):3-8. PubMed ID: 22173921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-Type Lectin-Like Molecule-1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study.
    Wang J; Wang W; Chen H; Li W; Huang T; Zhang W; Ling W; Lai P; Wang Y; Geng S; Li M; Du X; Weng J
    Biomed Res Int; 2021; 2021():6643948. PubMed ID: 33778076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperative CAR targeting to selectively eliminate AML and minimize escape.
    Haubner S; Mansilla-Soto J; Nataraj S; Kogel F; Chang Q; de Stanchina E; Lopez M; Ng MR; Fraser K; Subklewe M; Park JH; Wang X; Rivière I; Sadelain M
    Cancer Cell; 2023 Nov; 41(11):1871-1891.e6. PubMed ID: 37802054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell Activity against AML Improved by Dual-Targeted T Cells Stimulated through T-cell and IL7 Receptors.
    Krawczyk E; Zolov SN; Huang K; Bonifant CL
    Cancer Immunol Res; 2019 Apr; 7(4):683-692. PubMed ID: 30782669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis.
    van Loo PF; Hangalapura BN; Thordardottir S; Gibbins JD; Veninga H; Hendriks LJA; Kramer A; Roovers RC; Leenders M; de Kruif J; Doornbos RP; Sirulnik A; Throsby M; Logtenberg T; Dolstra H; Bakker ABH
    Expert Opin Biol Ther; 2019 Jul; 19(7):721-733. PubMed ID: 31286786
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.